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Background: Oral monotherapy anticoagulation has facilitated home treatment of venous 
thromboembolism (VTE) in outpatients.
Objectives: The aim of this study was to measure efficacy, safety, as well as patient and physi-
cian perceptions produced by a protocol that selected VTE patients as low-risk patients by the 
Hestia criteria, and initiated home anticoagulation with an oral factor Xa antagonist.
Methods: Patients were administered the Venous Insufficiency Epidemiological and Eco-
nomic Study Quality of life/Symptoms ques tionnaire [VEINEs QoL/Sym] and the physical 
component summary [PCS] from the Rand 36-Item Short Form Health Survey [SF36]). The 
primary outcomes were VTE recurrence and hemorrhage at 30 days. Secondary outcomes 
compared psychometric test scores between patients with deep vein thrombosis (DVT) to 
those with pulmonary embolism (PE). Patient perceptions were abstracted from written 
comments and physician perceptions specific to PE outpatient treatment obtained from 
structured survey.
Results: From April 2013 to September 2015, 253 patients were treated, including 67 with PE. 
Within 30 days, 2/ 253 patients had recurrent DVT and 2/253 had major hemor rhage; all four 
had DVT at enrollment. The initial PCS scores did not differ between DVT and PE patients 
(37.2±13.9 and 38.0±12.1, respectively) and both DVT and PE patients had similar improve-
ment over the treatment period (42.2±12.9 and 43.4±12.7, respectively), consistent with prior 
literature. The most common adverse event was menorrhagia, present in 15% of women. Themes 
from patient-written responses reflected satisfaction with increased autonomy. Physicians’ 
(N=116) before-to-after protocol comfort level with home treatment of PE increased 48% on 
visual analog scale.
Conclusion: Hestia-negative VTE patients treated with oral monotherapy at home had low 
rates of VTE recurrence and bleeding, as well as quality of life measurements similar to prior 
reports.
Keywords: anticoagulants, quality of life, patient preference, menorrhagia, patient outcome 
assessment, health care, comorbidity, hemorrhage, pulmonary embolism
Introduction
Widening use of monotherapy to treat venous thromboembolism (VTE), including deep 
vein thrombosis (DVT) and pulmonary embolism (PE), has facilitated the treatment 
of low-risk patients with VTE at home without the need for hospitalization. In our 
previous work, we reported the 1-year experience of a protocol (the “Indy protocol”) 
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that included 106 patients who were diagnosed with VTE 
(including 35 with PE) in the emergency department (ED).1 
These patients were determined to be at low risk for adverse 
outcomes using the Hestia criteria and were discharged 
from the ED with treatment with rivaroxaban. We believe 
that clinicians continue to be cautious about discharging 
patients with PE, possibly because of concerns that a patient 
discharged with PE may return within a few weeks with 
cardiovascular collapse or major hemorrhage.2,3
In this manuscript, we report the efficacy (VTE recur-
rence) and safety (bleeding) outcomes, as well as results 
of psychometric testing from 2 years of experience with 
the Indy protocol with two comparisons: 1) outcomes 
of patients with PE to those who had isolated DVT; and 
2) patients treated with the Indy protocol to published results 
of psychometric testing from prior literature for patients 
treated with heparin and a vitamin K antagonist (VKA). The 
rationale for the first comparison is that outpatient treatment 
of DVT is a widely recommended standard of care,4 but 
outpatient treatment of PE is a new concept. Given that PE 
can cause sudden death, some clinicians may be hesitant 
to adopt the practice of discharging patients with PE. 
Therefore, a head-to-head comparison of outcomes of 
patients with DVT and PE treated as outpatients may help 
inform clinicians on the risks and benefits of this outpatient 
treatment for PE. The rationale for the second comparison 
comes from the fact that home treatment with oral mono-
therapy is also a new concept, and we believe it is valuable 
to compare the quality-of-life survey results from the Indy 
protocol to published results of VTE patients treated with 
heparin–VKA.5,6 We also report the written thoughts and 
perceptions of patients about the protocol. Finally, we 
surveyed clinicians for their perceptions regarding their 
comfort, concerns, and knowledge about outpatient dis-
charge of VTE patients.
Our quantitative hypotheses were as follows: that 
PE patients would not differ from patients with DVT in 
1) their Charlson comorbidity index, 2) normalized physical 
component summary (PCS) score of the 36-Item Short 
Form Health Survey 36 (SF36), or 3) the 30-day frequency 
for the composite end point of either recurrent VTE or 
bleeding; and that psychometric testing would show quality 
of life measurements similar to previously reported data for 
VTE patients, assessed using the PCS for all VTE patients 
and the validated Venous Insufficiency Epidemiological and 
Economic Study Quality of life/Symptoms questionnaire 
(VEINES QoL/Sym) survey for DVT patients.5,6
Methods
study design
This was a preplanned outcomes study that was part of a 
published protocol for the immediate discharge and further 
management of low-risk VTE from the ED using a novel 
target-specific anticoagulant.1 The protocol was approved as a 
research study by the Indiana University Institutional Review 
Board and is a registered observational trial (NCT02079584). 
All patients gave written informed consent to participate. 
In the first year of the study, 100% of patients were referred 
solely from two academic EDs (Eskenazi Health and 
Methodist Hospital, both teaching hospitals with residen-
cies in emergency medicine in Indianapolis, IN, USA). Both 
emergency departments employ board-certified emergency 
physicians and emergency medicine residents. In the second 
year of the protocol (starting June 2014), we began accepting 
outpatients from other clinics, primarily orthopedic surgery 
and trauma clinics.
study protocol
All patients had image-confirmed DVT or PE. To refer 
a patient, clinicians had to either complete an electronic 
survey (described previously1) or contact a study author by 
telephone to confirm that the patient was at low risk using 
the Hestia criteria with two modifications: patients were 
excluded for .2 doses of intravenous narcotics, rather than 
the original requirement of “severe pain requiring intrave-
nous narcotics .24 hours”, and patients were excluded for 
a pulse oximetry reading ,95% instead of ,90%. Patients 
with active malignancy were further risk stratified using the 
POMPE-C (prediction of mortality from pulmonary embolism 
with cancer) tool.7
Patients were prescribed rivaroxaban 15 mg twice per day 
for 21 days, followed by a 1-month prescription for 20 mg 
once per day. Access to medications was facilitated by our 
case management team, which consists of registered nurses. 
Patients returned to one of two clinics, held on the second 
and fourth Fridays of each month, with one visit scheduled 
at ~3 weeks of diagnosis and a follow-up visit scheduled at 
3–6 months. The day-to-day operations of the clinics are 
run by pharmacists at one site and nurse practitioners at 
the other.
Patient-centered outcomes included data collected at 
three time points: 1) at diagnosis, including clot location, 
demographics, payer status, vital signs, past medical history, 
Charlson comorbidity index, and laboratory values; 2) at the 
initial clinic visit, including the Rand SF36 quality of life 
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survey, the VEINEs QoL/Sym survey, and patient overall 
perception of health (on a scale of 1–10); 3) outcome data 
for the first 30 days after diagnosis, including any ED 
visits, hospital admission for any reason, VTE recurrence, 
demonstrated by image-proven thrombosis at a new loca-
tion (limb or lung), and any major or clinically relevant 
nonmajor bleeding event, using previously described explicit 
definitions.8
The psychometric testing listed here was obtained from 
as many patients as was reasonably possible within the con-
straints of personnel, time, and patient willingness. At the 
initial visit, a medical student participating in a research 
elective also administered a questionnaire to record patients’ 
free text written responses to three questions: “Describe your 
overall reaction to being treated at home and the clot clinic”, 
“What were your main concerns about being discharged 
home from the emergency department?” and “What would 
you like us to do differently?” The students administering the 
questionnaires were trained by the investigators on how to 
deliver the surveys, including instructions to tell patients 
that their responses were optional and had no bearing on 
their medical care. Students were instructed to give patients 
as much time as they needed to answer the questions in the 
privacy of their own room in clinic and to inform patients 
of the option of giving verbal answers.
Follow-up data were obtained as previously described,1 
including data collected on a structured collection form 
from the patient in the clinic, supplemented by telephone 
calls by a research coordinator to the patient in the event of 
a missed clinic appointment, followed by medical record 
review. Patients were asked about repeat visits, VTE diag-
nosis, and bleeding. Medical records were also reviewed 
by an experienced research coordinator to extract data on 
returns to ED, readmissions, VTE recurrence, and bleed-
ing incidence within 30 days after initial diagnosis. The 
coordinator used explicit definitions for each variable. A 
10% random sample was assessed by a second observer, 
and interobserver variability was measured for the end 
points of VTE and bleeding; the observers were found to 
have 100% agreement.
To obtain perceptions from clinicians, we created a 
survey in REDCap that asked eight questions about their 
perceptions of the protocol. This was performed after 1 year 
of protocol implementation. Questions were designed to 
assess clinician perceptions of the protocol, including the 
impact on their comfort level and frequency of discharging 
patients with PE.
Data analysis
The PCS, Charlson, and VEINEs QoL data were recorded 
and the responses were converted into scores according 
to published methods.9–13 We compared the means of the 
Charlson index, PCS, and VEINEs QoL between PE and 
DVT patients with an unpaired t-test. Changes in PCS and 
VEINEs QoL from immediately postdiagnosis to 3–6 month 
follow-up were compared with a paired t-test. Proportions of 
patients with revisits to the ED, admissions, VTE recurrence, 
and bleeding were compared between PE and DVT with 95% 
confidence interval (CI) for the difference. This was primarily 
a qualitative study of all existing patients in the clinic, thus 
no formal sample size was calculated a priori.
Based upon prior literature, the study population was 
assumed to be similar to prior outpatient VTE populations 
for PCS and VEINEs QoL values within one standard error 
of the mean: for the PCS, 38±1 at diagnosis and 42±1 at 
3–6 months postdiagnosis; for the VEINES QoL, 50±1 at 
diagnosis and 55±1 3–6 months later.5,10 Survey results from 
clinicians are presented as descriptive data.
Patient free text responses were recorded in their own 
handwriting, and labeled with an identifier, and copied for 
coding. Coding was done by the three authors (ZPK, JAK, and 
DMB), who independently examined the written responses of 
patients and coded them using three criteria: relevance of the 
response to the clinic and VTE treatment (low or high), clar-
ity of the point (low or high), and perceived importance (low 
or high), based upon frequency of expression by more than 
half of patients. Topics deemed not relevant included patient 
expressions about other medical providers unrelated to their 
problem, ED processes, or issues related to opiate pain medi-
cines and neutral or nonresponsive comments (eg, “I just want 
to get better”). The three authors by consensus then selected 
excerpts that represented the credible themes, attempting to 
include both positive and negative perceptions.
Results
Figure 1 shows the flow diagram of patients enrolled. From 
April 2013 until September 2015, we enrolled 253 unique 
Hestia-negative VTE patients, including 67 with PE who were 
registered from either of the two participating EDs using the 
survey tool. Of the 253 patients, 209 (83%) had at least one 
visit to our follow-up clinic, 35 (14%) who followed up with 
a personal physician only, and nine (3.5%) patients who were 
noncompliant with medical follow-up. We conducted paired 
(initial [2–4 week] and follow-up [3–6 months]) psychometric 
testing on 171 patients (67%) and telephone and medical 
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record follow-up for all 253 patients. Table 1 shows the 
vital signs and demographic data, including payer informa-
tion. When mean values of demographics and vitals were 
compared for PE versus DVT (comparisons not shown), the 
only significant difference was that PE patients were younger 
than DVT patients (41.5±14.8 years versus 49.1±15.9 years; 
P=0.001 from unpaired t-test). Patients were relatively young, 
with a high proportion of minorities and ethnicities, and about 
one-half had an income level at or below that required for 
Indiana Medicaid. Regarding the need for an ED-based pro-
tocol (as opposed to an office setting), the diagnosis of VTE 
was made between the hours of 7 pm and 7 am in 62 (25%) 
patients and on a weekend in 45 (18%) patients.
Table 2 presents clot locations. Seventy-eight patients 
had clots in more than one anatomic site, including seven 
with both PE and DVT, and ten with bilateral leg DVT. 
Among the PE patients, 25 (37% of PE) had bilateral PE, and 
16 had isolated subsegmental PE (23% of PE). Minor clot 
$Q\SDWLHQWZLWKYHQRXVWKURPERHPEROLVPDWWZRKRVSLWDOHPHUJHQF\GHSDUWPHQWVD$SULO±$XJXVW
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<HV3(Q 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+HVWLDSRVLWLYHRURWKHUUHDVRQWRDGPLW"
1R'97Q GLVFKDUJHG3(Q GLVFKDUJHG
Q )ROORZXSDW§GD\VLQSURWRFROVSHFLILFFOLQLF
1 6HOIPDQDJHGWKHUDS\WHOHSKRQHDQGPHGLFDOUHFRUGIROORZXSRQO\
Q )ROORZXSE\WHOHSKRQHDQGZLWKSULPDU\FDUHSK\VLFLDQ
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Q 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Figure 1 Flow diagram of patient enrollment and outcomes.
Note: ahospitals include Wishard (now eskenazi) and Methodist hospitals, both in indianapolis, in, UsA.
Abbreviations: DVT, deep vein thrombosis; h, hours; inPc, indiana network for Patient care; Pe, pulmonary embolism; ssDi, social security Death index.
Table 1 clinical and social features of the population
Continuous variables Mean Standard deviation
Age, years 47.0 16.1
heart rate, beats/min 85.7 16.8
respiratory rate, breaths/min 17.4 2.6
systolic blood pressure, mmhg 137.0 24.1
Diastolic blood pressure, mmhg 82.3 15.0
saO2, % 97.7 1.6
Body weight, Kg 100.8 43.9
BMi, Kg/m2 35.5 15.3
Categorical variables N % of 253
non-caucasian race 127 50%
hispanic 15 6%
Female 113 45%
Medicaid 101 40%
self-pay 36 14%
Medicare 27 10%
PPO/private insurance 87 34%
Abbreviations: BMi, body mass index; PPO, preferred provider organization.
Table 2 clot characteristics
Location Na Percent of total
left leg 91 36.0%
right leg 72 28.5%
left arm 5 2.0%
right arm 5 2.0%
Axillary vein 1 0.4%
calf vein 45 17.8%
Femoral vein 41 16.2%
saphenous vein 14 5.5%
Other vein 30 11.9%
left lung 36 14.2%
right lung 51 20.2%
subsegmental 16 6.3%
segmental or multiple subsegmental 38 15.0%
lobar or larger pulmonary artery 13 5.1%
Unprovoked 173 68.5%
Note: asum of clot locations exceeds 253 because some patients had clots in more 
than one location.
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locations included isolated calf vein or isolated saphenous 
vein thrombosis, found in 23 patients (12% of DVT). The 
majority (69%) of clots were unprovoked.
Table 3 presents the frequency of abnormal laboratory 
values. The protocol required a basic metabolic package 
and complete blood count, but this was missing in 29/253 
(11%) of patients. Forty percent of patients had elevated 
blood glucose, leukocytosis, or anemia. None had elevated 
troponin level, but three of 19 (16%) had an elevated brain 
natriuretic peptide concentration.
Table 4 shows the comorbidities in the sample and 
demonstrates that the majority of patients (67%) had a 
Charlson comorbidity index $1. For the entire sample, the 
mean Charlson comorbidity index was 1.8±2.6, and when 
compared between patients with PE and DVT, this value 
was not statistically significant (1.4±2.4 versus 2.0±2.0; 
P=0.146).
Table 5 presents data from the standard history and 
physical form used in the clinic, and only shows data for 
the first 30 days (ie, at the 2–4 week visit). The most com-
mon care process problem was difficulty in accessing the 
drug, in most cases related to need for preauthorization or 
the patient’s inability to afford the copayment required for 
part D Medicare. The most frequent medical problem was 
menorrhagia, which occurred in 7% of the entire population 
and 15% of women. Two patients among the 253 (0.8%, 95% 
CI: 0.1%–1.9%) had major hemorrhage, and two patients had 
recurrent VTE (both DVT) within 30 days.
Psychometric testing
Figures 2–4 compare the results of initial and follow-up psy-
chometric testing for the 171 patients obtained in the clinic 
or by telephone follow-up between patients with PE (N=65) 
and DVT (N=106). These 171 patients did not differ (P.0.1 
unpaired t-test or chi-square test) for any variable in Table 1 
or Table 4, compared with the 82 patients with missing data. 
Measurements were made at 3 weeks after diagnosis and then 
again at 3–6 months. Table 5 offers several salient points. 
First, in response to the question about overall health on a 
1–10 scale (1= worst, 10= best), PE and DVT patients started 
at similar levels, but PE patients reported more improvement 
(from 3.5±2.5 to 4.7±3.1) than DVT patients (from 3.3±1.9 to 
3.2±2). Second, the first normalized VEINEs QoL result for 
our entire VTE population (51±6) fell within the previously 
reported range of 50±1 for warfarin-based regimens.5,10 
Table 3 Abnormal laboratory values
Laboratory value n/N %
Troponin elevated (.99 percentile for cV ,10%) 0/47 0
BnP .90 pg/ml 3/19 16
Blood glucose .150 mg/dl in eD 30/224 13
White blood count .10,000/μl 46/224 21
hemoglobin ,10 g/dl 12/224 5
creatinine .1.5 mg/dl 9/224 4
Abbreviations: BnP, brain natriuretic peptide; eD, emergency department; 
n, number with laboratory value abnormal; n, total number of laboratory done; 
CV, coefficient of variability.
Table 4 comorbid conditions and illness severity
Comorbidity component n % of 253
Active malignancy 7 3
smoker 100 40
Oral contraceptive use 9 4
recent miscarriage 1 0.4
Postpartum status (,6 weeks) 6 2
cOPD 18 7
heart failure 9 4
Diabetes mellitus 51 20
hypertension 97 38
cAD, no prior Mi 13 5
cAD, prior Mi 6 2
chronic kidney disease, non-dialysis-dependent 9 4
Alcoholism 14 6
charlson comorbidity index 0 83 33
charlson comorbidity index 1–2 113 45
charlson comorbidity index 3–4 29 11
charlson comorbidity index .4 28 11
Abbreviations: cAD, coronary artery disease; cOPD, chronic obstructive 
pulmonary disease; Mi, myocardial infarction.
Table 5 Patient-centered outcomes and complications within 
30 days postdischarge
Outcome n % of 253
Trouble getting drug? 19 7.5
gum bleeding 8 3.2
hematuria 0 0.0
Blood in stool 3 1.2
easy bruising 7 2.8
Prolonged menstruation 1 0.4
heavy menstruation 17 6.7
Unscheduled eD or clinic visit 29 11.5
rehospitalization within 30 days 4 1.6
repeat evaluation for DVT 5 2.0
rehospitalization for recurrent DVT 1 0.4
repeat evaluation for Pe 3 1.2
Bleeding complications requiring hospitalizationa 2 0.8
Bleeding complications with transfusion of PrBcs 2 0.8
rehospitalization for other diagnoses 2 0.8
complications within 30 days (renal failure, liver 
failure, stroke, and Mi)
0 0
Death 0 0
Note: aBoth patients satisfy the definition of major bleed.
Abbreviations: DVT, deep vein thrombosis; eD, emergency department; 
Mi, myocardial infarction; Pe, pulmonary embolism; PrBc, packed red blood cells.
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The first VEINEs QoL mean score was not different between 
PE vs DVT patients (P=0.13), but those with DVT had larger 
increases on the second administration of the survey (from 
48±6 to 73±7; P,0.001 paired t-test). Only seven patients 
with PE had diagnosed DVT. Third, the first PCS mean score 
for the entire population was 37.7±12.7, which was within 
the predicted range of 38±1 based on prior literature. The 
entire population showed a significant increase in PCS to 
43.2±12.5 on the second survey (P=0.021, paired t-test), at 
the upper end of the predicted value of 42±1. Patients with 
PE and DVT showed similar increases in the PCS.
excerpts of patient statements
The coders recognized three themes: 1) favorable reactions 
to the presence of a clot-focused clinic (65% of perceptions); 
2) positive perceptions about the anticoagulant medication, 
particularly surrounding the absence of required testing 
(55%); and 3) concerns about why they had a clot, and ques-
tions about how to reduce the chances of future clots (48%). 
Patients who had prior experience with warfarin also gener-
ally expressed positive statements about not having to take 
injections, with one notable dissenting patient expressing con-
cern that she was not being “followed as closely”. The authors 
selected nine quotes representative of these themes:
I was worried about not seeing the nurses in Coumadin 
clinic as often, but I felt better having the doctor’s phone 
number, I can call anytime.
I don’t stick my finger for my blood sugar, I’m sure not 
going to do it for my blood clot.
So I can go to New York for a month, and I don’t have to 
follow up with anybody?
I believe Xarelto is better than taking coumadin blood 
thinners, being hospitalized, getting blood drawn on + off + 
whatever else comes with coumadin.
[…] I didn’t want to stay in the hospital anymore. Thanks 
to this medicine I was able to go home. Glad that no needle-
sticks are required.
I believe that being treated at home was my best option.
I feel they saved me … would much rather do this program 
instead of shots.
I am not worried about the next few months but am con-
cerned about the long term.
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Figure 3 Veines Qol/sym scores.
Note: **P,0.05 vs Pe, unpaired t-test; and P,0.05 vs 2–4 weeks, paired t-test.
Abbreviations: DVT, deep vein thrombosis; Pe, pulmonary embolism; Veines 
QoL/Sym, Venous Insufficiency Epidemiological and Economic Study Quality of life/
symptoms questionnaire.
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Figure 4 normalized physical component summary (Pcs) scores from the standard 
form 36. 
Note: *P,0.05 vs 2–4 weeks, paired t-test.
Abbreviations: DVT, deep vein thrombosis; Pcs, physical component summary; 
Pe, pulmonary embolism.
Figure 2 Patient response to question “On a scale of 1–10, with one being perfectly 
normal and ten being near death, how would you rate yourself?”
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Physician survey
We received responses from 89% of the clinicians surveyed 
(n=119). In response to the question “Prior to Clot Clinic 
(Indy Protocol), how comfortable would you have been 
discharging what you would consider a low-risk PE?”, the 
mean (±standard deviation) from the visual analog scale was 
17.6±16.9 mm (0 mm = uncomfortable, 100 mm = highly 
comfortable); in response to the question “Would you cur-
rently feel comfortable sending home low-risk PE patients if 
they meet the Indy Protocol criteria?”, this value increased 
to 66.0±25.6 mm. Counts and frequencies of clinician 
responses to the question “If patients meet discharge criteria, 
what remaining concerns prevent you from sending them 
home? (Select all that apply)” were as follows: I haven’t 
done it before/it’s too unfamiliar: 48 (40.3%); I’m not con-
vinced the data support safe discharge: seven (5.9%); I feel 
more comfortable if the patient is hospitalized: 25 (21.0%); 
The patients I have approached don’t want to go home: 
14 (11.8%); I need to discuss with an expert beforehand: 
nine (7.6%); I’m too worried that I am medicolegally liable: 
29 (24.4%); Rivaroxaban might be too expensive: 39 (32.8%); 
It is easier to admit than discharge these patients: 25 (21.0%); 
I worry they need a thrombophilia workup: 12 (10.1%); and I 
have no concerns if they meet criteria: 27 (22.7%).
In response to the question “Of the ELIGIBLE patients 
you have seen in the past year, what percent have you 
APPROACHED about outpatient treatment?”, the mean 
(±standard deviation) of 119 responses was 82.1%±24.8%. 
Finally, the mean response to the question “Of the patients 
you have approached, what percent do you think have agreed 
to outpatient therapy?” was 81.5%±25.0%. Analysis of 63 
free text responses revealed that 80% indicated the need for 
dedicated follow-up as the most important factor to their 
decision to treat PE at home.
Discussion
These data provide the first evidence of the safety, efficacy, 
and positive patient-centered outcomes associated with 
outpatient treatment of PE and DVT using monotherapy 
oral anticoagulation. Results indicate a low rate of VTE 
recurrence (two of the total 253, including zero of the 67 
with PE) and major bleeding (also two of 253 total, includ-
ing zero of 67 with PE) in the first 30 days after discharge. 
Psychometric scores were similar to those previously pub-
lished in VTE patients treated with heparin and then oral 
VKA.5,6,10 Although the sample size is small, we provide 
preliminary evidence that psychometric outcomes were 
similar between patients with PE compared with patients 
with DVT.
When surveyed 1 year after implementation of the pro-
gram, physicians expressed more comfort with discharging 
patients with PE, primarily because of assured follow-up. 
In the free text written comments, patients generally 
expressed appreciation and reduced anxiety because of the 
availability of a published protocol, a dedicated clinic, and 
ready access to the clinicians who run the clinic. Negative 
issues included problems with access to drug in 7.5% of 
patients, primarily related to problems with preauthoriza-
tions for private insurance and the “doughnut hole” in 
Medicare part D. We also emphasize that access to drug 
was facilitated by the use of case workers in the EDs who 
assisted in qualifying low-income, uninsured patients for a 
patient assistance program. Another potential concern was 
the high rate of menorrhagia after starting rivaroxaban, 
reported by 15% of women, requiring hysterectomy in one 
patient. In general, our approach to menorrhagia has been 
to recommend holding one dose of rivaroxaban, a strategy 
that we believe has been effective for most cases. No patient 
with menorrhagia required switching from rivaroxaban to 
another anticoagulant.
These data may help increase comfort level of patients 
and providers with outpatient treatment of PE. Our own 
survey data show that clinicians are hesitant to treat PE at 
home, despite most clinicians believing that home treatment 
of DVT is standard of care (level 1B recommendation from 
the American College of Chest Physicians).4 We believe that 
these data help justify the extension of this standard care for 
DVT to include home treatment of low-risk patients with PE. 
The data enable providers to inform patients with PE or DVT 
that if they are treated at home, their quality of life is likely 
to be as good as when they are hospitalized and is likely to 
improve with time. We also submit that the low rates of major 
hemorrhage and recurrent VTE comprise important informa-
tion for patient education. Based upon prior work, patients are 
most concerned about the sequelae of hemorrhage (especially 
intracranial) and recurrent PE.14,15 Both our current patients’ 
comments and the authors’ collective experience argue for 
the pressing need for clinics that are dedicated to more than 
just the mechanical act of anticoagulation.
The dedicated clot clinic was important to the success of 
the Indy protocol. Clinicians indicated the need for follow-up 
as the most important component to their comfort with dis-
charging low-risk patients. Implementation of the clinic was 
associated with a 50% absolute increase in their expressed 
level of comfort. Likewise, more than one-half of patients 
wrote comments that indicated that they were specifically 
comfortable or satisfied with having a dedicated clinic for 
the care of their clots. The fact that other clinical specialties 
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(orthopedic surgery and trauma surgery) have begun using 
the clinic points to successful dissemination.
Limitations include the lack of a randomized design, 
meaning that we do not have a matched comparator group. It 
could be hypothesized that if patients with PE (or DVT) had 
been hospitalized, it is possible that their initial psychometric 
testing would have been different. However, comparing our 
data to previously reported VTE psychometric testing reveals 
similar values for the PCS.5,10 This potential deficit is also 
being addressed in an ongoing randomized controlled trial 
(NCT02584660). The CIs for VTE recurrence and bleeding 
extend as high as 3% in the PE subgroup. However, studies 
validating the Hestia criteria,16,17 including ours,1 have previ-
ously demonstrated safety. We only used rivaroxaban and 
have no data for other anticoagulants or outcomes in patients 
treated at home and cared for solely by other providers (eg, 
primary care provider).
Conclusion
Patients with acute DVT and PE diagnosed in the ED set-
ting, who were deemed of low risk by objective criteria and 
were treated with monotherapy anticoagulation, had similar 
degrees of comorbidities, similar outcomes in terms of VTE 
recurrence and bleeding, and equal scores on psychometric 
tests that assessed quality of life. Physicians indicated marked 
increase in comfort level from before to after implementa-
tion of the protocol with discharging patients with acute PE. 
Patients generally expressed preference for home treatment 
with monotherapy anticoagulation for both DVT and PE. 
These data support the use of an outpatient treatment protocol 
for DVT and PE.
Author contributions
JAK conceived and designed the study, performed primary 
analysis, and wrote the first draft of the manuscript. DMB 
participated in development of the protocol and implemen-
tation of the protocol, wrote the manuscript, collected data, 
and performed analysis. ZPK edited the protocol, collected 
and analyzed the data, helped write, and edit the manuscript. 
All authors contributed toward data analysis, drafting and 
critically revising the paper and agree to be accountable for 
all aspects of the work.
Disclosure
In the past 3 years, JAK has received research grant funding 
from the Patient-Centered Outcomes Research Institute and 
the National Institutes of Health, Mallingkrodt in addition 
to being a consultant to Janssen Pharmaceuticals. The other 
authors report no conflicts of interest in this work.
References
 1. Beam DM, Kahler ZP, Kline JA. Immediate discharge and home 
treatment of low risk venous thromboembolism diagnosed in two U.S. 
emergency departments with rivaroxaban: a one- year preplanned 
analysis. Acad Emerg Med. 2015;22:788–795.
 2. Kabrhel C, Okechukwu I, Hariharan P, et al. Factors associated with 
clinical deterioration shortly after PE. Thorax. 2014;69:835–842.
 3. Yoo HH, Queluz TH, El DR. Outpatient versus inpatient treatment for 
acute pulmonary embolism. Cochrane Database Syst Rev. 2014;11: 
CD010019.
 4. Kearon C, Akl EA, Comerota AJ, et al; American College of Chest 
Physicians. Antithrombotic therapy for VTE disease: antithrombotic 
therapy and prevention of thrombosis, 9th ed: American College of 
Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 
2012;141:e419S–e494S.
 5. Kahn SR, Shbaklo H, Lamping DL, et al. Determinants of health-related 
quality of life during the 2 years following deep vein thrombosis. 
J Thromb Haemost. 2008;6:1105–1112.
 6. Klok FA, van Kralingen KW, van Dijk AP, et al. Quality of life in 
long-term survivors of acute pulmonary embolism. Chest. 2010;138: 
1432–1440.
 7. Kline JA, Roy PM, Than MP, et al. Derivation and validation of a 
multivariate model to predict mortality from pulmonary embolism with 
cancer: the POMPE-C tool. Thromb Res. 2012;129:e194–e199.
 8. Schulman S, Kearon CP; Subcommittee on Control of Anticoagulation 
of the Scientific and Standardization Committee of the International 
Society on Thrombosis and Haemostasis. Definition of major bleeding 
in clinical investigations of antihemostatic medicinal products in non-
surgical patients. J Thromb Haemost. 2005;3:692–694.
 9. Hays RD, Sherbourne CD, Mazel RM. The RAND 36-item health 
survey 1.0. Health Econ. 1993;2:217–227.
 10. Kline JA, Kabrhel C, Courtney DM, et al. Treatment of submassive 
pulmonary embolism with tenecteplase or placebo: cardiopulmonary 
outcomes at three months (TOPCOAT): multicenter double-blind, 
placebo-controlled randomized trial. J Thromb Haemost. 2014;12: 
549–568.
 11. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of 
classifying prognostic comorbidity in longitudinal studies: development 
and validation. J Chronic Dis. 1987;40:373–383.
 12. Lamping DL, Schroter S, Kurz X, Kahn SR, Abenhaim L. Evaluation 
of outcomes in chronic venous disorders of the leg: development of 
a scientifically rigorous, patient-reported measure of symptoms and 
quality of life [see comment]. J Vasc Surg. 2003;37:410–419.
 13. Kahn SR, Lamping DL, Ducruet T, et al; VETO Study investigators. 
VEINES-QOL/Sym questionnaire was a reliable and valid disease-
specific quality of life measure for deep venous thrombosis. J Clin 
Epidemiol. 2006;59:1049–1056.
 14. Locadia M, Bossuyt PM, Stalmeier PF, et al. Treatment of venous throm-
boembolism with vitamin K antagonists: patients’ health state valuations 
and treatment preferences. Thromb Haemost. 2004;92:1336–1341.
 15. HOGG K, Kimpton M, Carrier M, Coyle D, Forgie M, Wells P. Estimating 
quality of life in acute venous thrombosis. JAMA Intern Med. 2013;173: 
1067–1072.
 16. Zondag W, den Exter PL, Crobach MJ, et al; Hestia Study Investigators. 
Comparison of two methods for selection of out of hospital treatment 
in patients with acute pulmonary embolism. Thromb Haemost. 2013; 
109:47–52.
 17. Zondag W, Vingerhoets LM, Durian MF, et al; Hestia Study Investiga-
tors. Hestia criteria can safely select patients with pulmonary embolism 
for outpatient treatment irrespective of right ventricular function. 
J Thromb Haemost. 2013;11:686–692.
Patient Preference and Adherence
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/patient-preference-and-adherence-journal
Patient Preference and Adherence is an international, peer-reviewed, 
open access journal that focuses on the growing importance of patient 
 preference and adherence throughout the therapeutic continuum. Patient 
satisfaction, acceptability, quality of life, compliance, persistence and their 
role in  developing new therapeutic modalities and compounds to optimize 
clinical  outcomes for existing disease states are major areas of interest for 
the  journal. This journal has been accepted for indexing on PubMed Central. 
The  manuscript management system is completely online and includes a very 
quick and fair peer-review system, which is all easy to use. Visit http://www.
dovepress.com/testimonials.php to read real quotes from published authors.
Patient Preference and Adherence 2016:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
569
Outpatient VTe treatment
